Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient

A. Balduzzi; G. Lucchini; H. H. Hirsch; S. Basso; M. Cioni; A. Rovelli; A. Zincone; M. Grimaldi; P. Corti; S. Bonanomi; A. Biondi; F. Locatelli; E. Biagi; P. Comoli

doi:10.1038/bmt.2010.221

Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient

A. Balduzzi, G. Lucchini, H. H. Hirsch, S. Basso, M. Cioni, A. Rovelli, A. Zincone, M. Grimaldi, P. Corti, S. Bonanomi, A. Biondi, F. Locatelli, E. Biagi, P. Comoli

Research output: Contribution to journal › Article › peer-review

104 Scopus citations

Abstract

Progressive multifocal leukoencephalopathy (PML) associated with polyomavirus JC (JCV) infection has been reported to be usually fatal in allogeneic hematopoietic SCT (HSCT) recipients. We present the case of a 19-year-old HSCT patient diagnosed with JCV-associated PML after prolonged immunosuppression for severe GVHD. No short-term neurological improvement was observed after antiviral treatment and discontinuation of immunosuppressive therapy. Donor-derived JCV Ag-specific CTLs were generated in vitro after stimulation with 15-mer peptides derived from VP1 and large T viral proteins. After adoptive CTL infusion, virus-specific cytotoxic cells were shown in the peripheral blood, JCV-DNA was cleared in the cerebrospinal fluid and the patient showed remarkable improvement. Adoptive T-lymphocyte therapy with JCV-specific CTLs was feasible and had no side effects. This case suggests that adoptive transfer of JCV-targeted CTLs may contribute to restore JCV-specific immune competence and control PML in transplanted patients.

Original language	English
Pages (from-to)	987-992
Number of pages	6
Journal	Bone Marrow Transplantation
Volume	46
Issue number	7
DOIs	https://doi.org/10.1038/bmt.2010.221
State	Published - Jul 2011
Externally published	Yes

Keywords

CTL
GVHD
adoptive Immunotherapy
allogeneic transplantation
polyomavirus JC
progressive multifocal leukoencephalopathy

Access to Document

10.1038/bmt.2010.221

Cite this

Balduzzi, A., Lucchini, G., Hirsch, H. H., Basso, S., Cioni, M., Rovelli, A., Zincone, A., Grimaldi, M., Corti, P., Bonanomi, S., Biondi, A., Locatelli, F., Biagi, E., & Comoli, P. (2011). Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplantation, 46(7), 987-992. https://doi.org/10.1038/bmt.2010.221

@article{5eeb7f6be9384c84ab5980cc0cdcccf3,

title = "Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient",

abstract = "Progressive multifocal leukoencephalopathy (PML) associated with polyomavirus JC (JCV) infection has been reported to be usually fatal in allogeneic hematopoietic SCT (HSCT) recipients. We present the case of a 19-year-old HSCT patient diagnosed with JCV-associated PML after prolonged immunosuppression for severe GVHD. No short-term neurological improvement was observed after antiviral treatment and discontinuation of immunosuppressive therapy. Donor-derived JCV Ag-specific CTLs were generated in vitro after stimulation with 15-mer peptides derived from VP1 and large T viral proteins. After adoptive CTL infusion, virus-specific cytotoxic cells were shown in the peripheral blood, JCV-DNA was cleared in the cerebrospinal fluid and the patient showed remarkable improvement. Adoptive T-lymphocyte therapy with JCV-specific CTLs was feasible and had no side effects. This case suggests that adoptive transfer of JCV-targeted CTLs may contribute to restore JCV-specific immune competence and control PML in transplanted patients.",

keywords = "CTL, GVHD, adoptive Immunotherapy, allogeneic transplantation, polyomavirus JC, progressive multifocal leukoencephalopathy",

author = "A. Balduzzi and G. Lucchini and Hirsch, {H. H.} and S. Basso and M. Cioni and A. Rovelli and A. Zincone and M. Grimaldi and P. Corti and S. Bonanomi and A. Biondi and F. Locatelli and E. Biagi and P. Comoli",

year = "2011",

month = jul,

doi = "10.1038/bmt.2010.221",

language = "English",

volume = "46",

pages = "987--992",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "7",

}

Balduzzi, A, Lucchini, G, Hirsch, HH, Basso, S, Cioni, M, Rovelli, A, Zincone, A, Grimaldi, M, Corti, P, Bonanomi, S, Biondi, A, Locatelli, F, Biagi, E & Comoli, P 2011, 'Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient', Bone Marrow Transplantation, vol. 46, no. 7, pp. 987-992. https://doi.org/10.1038/bmt.2010.221

TY - JOUR

T1 - Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient

AU - Balduzzi, A.

AU - Lucchini, G.

AU - Hirsch, H. H.

AU - Basso, S.

AU - Cioni, M.

AU - Rovelli, A.

AU - Zincone, A.

AU - Grimaldi, M.

AU - Corti, P.

AU - Bonanomi, S.

AU - Biondi, A.

AU - Locatelli, F.

AU - Biagi, E.

AU - Comoli, P.

PY - 2011/7

Y1 - 2011/7

N2 - Progressive multifocal leukoencephalopathy (PML) associated with polyomavirus JC (JCV) infection has been reported to be usually fatal in allogeneic hematopoietic SCT (HSCT) recipients. We present the case of a 19-year-old HSCT patient diagnosed with JCV-associated PML after prolonged immunosuppression for severe GVHD. No short-term neurological improvement was observed after antiviral treatment and discontinuation of immunosuppressive therapy. Donor-derived JCV Ag-specific CTLs were generated in vitro after stimulation with 15-mer peptides derived from VP1 and large T viral proteins. After adoptive CTL infusion, virus-specific cytotoxic cells were shown in the peripheral blood, JCV-DNA was cleared in the cerebrospinal fluid and the patient showed remarkable improvement. Adoptive T-lymphocyte therapy with JCV-specific CTLs was feasible and had no side effects. This case suggests that adoptive transfer of JCV-targeted CTLs may contribute to restore JCV-specific immune competence and control PML in transplanted patients.

AB - Progressive multifocal leukoencephalopathy (PML) associated with polyomavirus JC (JCV) infection has been reported to be usually fatal in allogeneic hematopoietic SCT (HSCT) recipients. We present the case of a 19-year-old HSCT patient diagnosed with JCV-associated PML after prolonged immunosuppression for severe GVHD. No short-term neurological improvement was observed after antiviral treatment and discontinuation of immunosuppressive therapy. Donor-derived JCV Ag-specific CTLs were generated in vitro after stimulation with 15-mer peptides derived from VP1 and large T viral proteins. After adoptive CTL infusion, virus-specific cytotoxic cells were shown in the peripheral blood, JCV-DNA was cleared in the cerebrospinal fluid and the patient showed remarkable improvement. Adoptive T-lymphocyte therapy with JCV-specific CTLs was feasible and had no side effects. This case suggests that adoptive transfer of JCV-targeted CTLs may contribute to restore JCV-specific immune competence and control PML in transplanted patients.

KW - CTL

KW - GVHD

KW - adoptive Immunotherapy

KW - allogeneic transplantation

KW - polyomavirus JC

KW - progressive multifocal leukoencephalopathy

UR - http://www.scopus.com/inward/record.url?scp=79960188497&partnerID=8YFLogxK

U2 - 10.1038/bmt.2010.221

DO - 10.1038/bmt.2010.221

M3 - Article

C2 - 20921942

AN - SCOPUS:79960188497

SN - 0268-3369

VL - 46

SP - 987

EP - 992

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 7

ER -

Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient

Abstract

Keywords

Access to Document

Fingerprint

Cite this